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Arterial ischemic stroke in HIV
Defining and classifying etiology for research studies
ABSTRACT
HIV infection, and potentially its treatment, increases the risk of an arterial ischemic stroke. Mul-
tiple etiologies and lack of clear case definitions inhibit progress in this field. Several etiologies,
many treatable, are relevant to HIV-related stroke. To fully understand the mechanisms and the
terminology used, a robust classification algorithm to help ascribe the various etiologies is
needed. This consensus paper considers the strengths and limitations of current case definitions
in the context of HIV infection. The case definitions for the major etiologies in HIV-related strokes
were refined (e.g., varicella zoster vasculopathy and antiphospholipid syndrome) and in some in-
stances new case definitions were described (e.g., HIV-associated vasculopathy). These case def-
initions provided a framework for an algorithm to help assign a final diagnosis, and help classify
the subtypes of HIV etiology in ischemic stroke. Neurol Neuroimmunol Neuroinflamm 2016;3:e254;
doi: 10.1212/NXI.0000000000000254
GLOSSARY
ACL 5 anticardiolipin antibodies; anti-b2GP1 5 anti–b2-glycoprotein I; APS 5 antiphospholipid syndrome; HSV 5 herpes
simplex virus; IgG 5 immunoglobulin G; LA 5 lupus anticoagulant; RPR 5 rapid plasma reagin; SVD 5 small vessel disease;
TB 5 tuberculosis; TOAST 5 Trial of Org 10172 in Acute Stroke Treatment; TTP 5 thrombotic thrombocytopenic purpura;
VDRL 5 Venereal Disease Research Laboratory; VZV 5 varicella zoster virus.
Stroke has become a prominent complication of HIV infection.1,2 Recent work suggests that the
outcome of HIV-related stroke is also poor.3 A variety of mechanisms has been postulated,
including opportunistic infections, cardio-thromboembolism, coagulopathy, and the incom-
pletely understood HIV-associated vasculopathy.4 In addition, antiretroviral therapy may itself
exacerbate ischemic stroke risk through several mechanisms.2,4 In some patients, multiple path-
ogenic processes may combine. Of the various types of stroke in people with HIV, arterial
ischemic stroke affecting the brain is most frequently described, and so is the focus of this
review.4
In the 1990s, approaches to studying the etiology of ischemic stroke advanced considerably
with the development of the TOAST (Trial of Org 10172 in Acute Stroke Treatment) classi-
fication.5 However, the TOAST classification was derived in a setting where HIV infection
was less prevalent; in these populations, approximately 75% of ischemic stroke patients are
classified into 1 of 3 main categories (i.e., large artery atherosclerosis, small vessel disease [SVD],
and cardio-thromboembolism).6 In contrast, in HIV-infected stroke populations, less than 50%
fall into the 3 main categories.7 The higher proportion in the generic categories (i.e., “other
determined,” and “undetermined”) is largely attributable to alternative causes and the
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occurrence of multiple etiologies in one indi-
vidual. Without a reliable classification sys-
tem, the study of HIV stroke, particularly its
epidemiology and pathogenesis, will be
inhibited.
Several types of vasculopathy have been
described in individuals with HIV infection,
including accelerated atherosclerosis, HIV-
associated vasculitis, a nonatherosclerotic
group with intimal hyperplasia but without
atherosclerosis or vasculitis, and a group with
radiologically and clinically defined SVD.4
While the larger vessel vasculopathies (e.g.,
the nonatherosclerotic group) may manifest
as large artery stroke, SVD may be more
important in HIV-associated neurocognitive
disorders8; the pathogenesis of both is
unclear. Greater consistency and accuracy
across studies will be achieved by a standard-
ized algorithm.
Recently, a ranked approach of applying
diagnostic test results, which allows for dif-
ferent levels of evidence, was developed for
defining the range of etiologies of encephali-
tis, which also facilitated new large prospec-
tive cohort studies.9,10 We therefore decided
to adopt a similar approach to help classify
the subtypes of HIV etiology in ischemic
stroke. Our proposed algorithm is presented
in figure 1.
METHODS During the preparation of a recent review of HIV
and stroke written by some of the present authors,4 it was clear
that some case definitions needed refining, and more detailed
consideration was needed in handling patients with multiple eti-
ologies. We therefore identified experts in the fields of HIV
infection and stroke and established a working group that
included a broad range of relevant specialists.
The first step was to determine the main etiologies of interest
for HIV-related arterial ischemic stroke; this was largely based on
the classification described previously (table 1).4 Collectively,
these etiologies should account for the majority of cases seen in
HIV-related stroke.
A working template was developed to enable discussions
between the group members. Ideas and proposals were discussed,
deliberated, clarified, and modified based on e-mail input from all
participants.
The diagnostic level of evidence used was not dissimilar from
the TOAST classification or variations of it.11–13 For tests that had
a “confirmed” diagnosis, there was Level A diagnostic evidence
(i.e., direct demonstration by gold standard diagnostic tests or
criteria) whereas for tests that determined a “probable” diagnosis,
there was Level B diagnostic evidence (i.e., indirect evidence or
less sensitive or specific tests or criteria). With the exception of
a lumbar puncture for CSF analysis, our suggested tests form part
of the usual workup for a stroke patient. Given that there are no
contraindications, the consensus was that a lumbar puncture was
justified to exclude infectious etiologies, irrespective of HIV stage
and age of the individual.
We also defined a minimum investigation workup to help
classify the different etiologies (table 2). The use of optimal
tests further improved the level of evidence for causation. We
then rationalized the ranking of the different etiologies to
form an algorithm. The emerging roles of potential bio-
markers were also considered. Our discussions formed the
basis of this document.
HANDLINGMULTIPLE ETIOLOGIES IN HIV-RELATED
STROKE: DEVELOPING THE ALGORITHM The entry
point of this algorithm. Arterial ischemic stroke. This is
based on the definition of the Stroke Council of the
American Heart Association/American Stroke
Association.14 Despite recent revisions to this case
definition, those presenting with an insidious onset
of cognitive deterioration associated with multifo-
cal SVD on brain imaging, may still be overlooked.
HIV infection. This is based on a positive antibody
test (HIV enzyme immunoassay or rapid HIV anti-
body test) and confirmed with Western blot, antigen
test, or PCR. In resource-poor settings, confirmation
is usually with a second antibody test using a different
manufacturer system.
A complete “minimum” assessment. All patients should
have at least the minimum set of investigations, as per
our proposed algorithm (table 2). In better resourced
settings, further investigations comprising the “opti-
mum” set will improve the level of evidence to con-
firm a stroke etiology.
The algorithm. Having defined the criteria for the dif-
ferent etiologies of stroke in HIV, we developed an
algorithm by which these etiologies would be consid-
ered (figure 1). For some, the causal role is clear, the
disease mechanism relatively well described, and there
are important treatment implications of making the
diagnosis. For other putative causes, the evidence
implicating them is less clear, and there are no direct
treatment implications. For example, if a patient had
evidence of both confirmed cardio-thromboembolic
and atherosclerotic stroke, because the cardio-
thromboembolic stroke has a high risk of recurrence
and a poorer prognosis if untreated, this ranked
higher.15,16 Hence, in deriving the algorithm, we
adopted a hierarchy so that better established and
treatable etiologies would be considered first. Thus,
opportunistic infections were considered first, then
cardio-thromboembolism, vasculitis, atherosclerotic
or nonatherosclerotic vasculopathy, coagulopathies,
and finally SVD. The evidence for these etiologies
is discussed later.
Where there was evidence of multiple etiologies,
a confirmed diagnosis would override any etiologies
with evidence only for a probable diagnosis. If
there was no confirmed diagnosis, then multiple
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probable diagnoses would be accepted. What has
previously been the undetermined category has
been reclassified in our algorithm as follows: (1)
incomplete, defined by less than minimum tests
completed; (2) multifactorial stroke, defined by 2
or more “probable” etiologies at the same level;
and (3) cryptogenic stroke, defined by a complete-
minimum workup of tests but no etiology identi-
fied. This was further subdivided into (1)
cryptogenic embolism (based on a radiology crite-
rion),17 and (2) other cryptogenic—those not ful-
filling the criteria for cryptogenic embolism.17 In
the absence of invasive or noninvasive angiography,
cryptogenic* stroke should be adopted, in which
the asterisk denotes the absence of angiography.
STRENGTHS AND LIMITATIONS OF CURRENT
CASE DEFINITIONS FOR WELL-RECOGNIZED
ETIOLOGIES IN HIV-RELATED ARTERIAL
ISCHEMIC STROKE Opportunistic infections. Myco-
bacterium tuberculosis (TB), Cryptococcus, varicella zos-
ter virus (VZV), and syphilis are key infections
recognized to cause stroke in people with HIV
(table 3).4 Although they are more common in
Figure 1 An algorithm to define the etiology of HIV-related ischemic stroke for research studies
Minimum battery of tests include the following: HIV test, full blood count and blood film and urine dipstix assay, anticardiolipin antibodies, lupus anticoag-
ulant, anti–b2-glycoprotein, hemoglobin for sickle cell disease, serum syphilis treponemal (immunoassay1 agglutination test) and nontreponemal tests, chest
x-ray, CSF—microscopy, biochemistry, India ink and acid fast bacilli stains, blood culture, tuberculosis culture, unenhanced CT, ECG, and carotid/vertebral
duplex ultrasound and echocardiography. APS 5 antiphospholipid syndrome; OI 5 opportunistic infection; TTP 5 thrombotic thrombocytopenic purpura.
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the immunosuppressed, coinfection (with HIV) in
the immunocompetent is still pathogenic.
Tuberculous meningitis. TB in the CNS manifests in
many ways, but the most common form, and that
which most often leads to stroke, is tuberculous men-
ingitis. The mechanism is through an obliterative en-
darteritis or vasospasm. The gold standard for
diagnosing tuberculous meningitis is by isolating
the bacillus in the brain or CSF. However, this is
often difficult.18 Marais et al.18 have therefore devel-
oped a scoring algorithm for research studies based on
clinical, CSF, imaging findings, and evidence of TB
elsewhere.
Cryptococcus. A stroke occurs in cryptococcal men-
ingitis because of irritation of subarachnoid blood
vessels, resulting in vasospasm or endarteritis from
inflammation.19 Although culture of Cryptococcus
from the CSF is the gold standard, in the context of
symptomatic meningitis and a good sample volume of
CSF, the sensitivity and specificity of India ink
microscopy or cryptococcal antigen is greater than
90%, nearing 100% for cryptococcal antigen, and
so this is often accepted.20 TB and cryptococcal
infection arise more often in the immunosuppressed
(i.e., CD41 count ,200 cells/mm3).21,22 Abnormal
pleocytosis in the context of HIV typically accompa-
nies these infections when the CD41 count is $200
cells/mm3.21,22 We therefore recommend routine TB
and cryptococcal testing in those with a CD41 count
,200 cells/mm3, and restricted testing to those with
CSF pleocytosis at $200 cells/mm3.
Syphilis. Stroke is a meningovascular complication
of syphilis infection. A positive syphilis blood result
can be a challenge to interpret in HIV populations.
For example, HIV and antiphospholipid syndrome
(APS) can give false-positive results using nontrepo-
nemal methods.23 Current recommendations suggest
that a screening blood treponemal test (e.g., enzyme
immunoassays) should be followed by an additional
confirmatory treponemal test (e.g.,Treponema pallidum
particle agglutination assay), and if both of these are
positive, a nontreponemal blood test (e.g., Venereal
Disease Research Laboratory [VDRL] or rapid plasma
reagin [RPR]) should be performed to determine
whether this is active or previous disease.24 Having
established active peripheral disease, neurosyphilis is
diagnosed by a positive CSF VDRL or the less sensitive
RPR.25 Because CSF VDRL/RPR can be negative dur-
ing the early and late stages of neurosyphilis, CSF pleo-
cytosis can be used to make a presumptive diagnosis.
However, HIV is also associated with a CSF pleocy-
tosis ($5 cells/mm3), and some have suggested a cut-
off of greater than 20 cells be used to diagnose
neurosyphilis.26 CSF–fluorescence treponemal anti-
body test is sensitive for neurosyphilis but less spe-
cific than CSF VDRL/RPR in symptomatic cases
Table 2 Tests required to help define the etiology of HIV-related ischemic stroke
Minimum Optimum
Blood tests Hematology: FBC and blood film, antiphospholipid screen (younger than
55 years): lupus anticoagulant, anticardiolipin antibody, and anti–b2-
glycoprotein 1. Hb SS (to exclude sickle cell anemia); microbiology/
virology: HIV, treponemal (immunoassay 1 agglutination test) and
nontreponemal tests, blood culture (temperature $37.5°C or raised
C-reactive protein), VZV-IgG
Hematology: Clotting profile, fibrinogen, ADAMTS13 levels, and anti-
ADAMT313 antibody; biochemistry: U 1 E, LDH; microbiology:
hepatitis B 1 C
CSF analysis Microbiology: Microscopy (white cell/red cell count), standard bacterial
culture, for acid fast bacilli stains, Indian ink microscopy, TB/
cryptococcal culture—test all patients with a CD41 ,200 cells/mm3,
and among those with a CD41 count $200 cells/mm3, test only if CSF
WCC is .20 cells/mm3; biochemistry: glucose and protein
Microbiology/virology: CSF VZV-IgG index (if blood VZV-IgG is positive)
and VZV PCR; VDRL/RPR/chemokine (C-X-C motif) ligand 13 (if syphilis
blood screen is positive); cryptococcal antigen (test all patients with
a CD41 ,200 cells/mm3, and among those with a CD41 count $200
cells/mm3, test only if CSF WCC is .20 cells/mm3)
Histopathology Brain biopsy/postmortem analysis when possible
Imaging Brain imaging: Unenhanced head CT (the ideal should include a CT, head
MRI, and noninvasive angiography of cerebral and cervical vessels using
magnetic resonance or CT angiography); chest x-ray; ultrasound:
carotid/vertebral duplex (only done in the absence of noninvasive
angiography of cerebral and cervical vessels using magnetic resonance
or CT angiography); ultrasound: transthoracic echocardiography
Brain imaging: Head CT or head MRI with contrast (minimum
sequences: T2, T2*GRE, FLAIR, and DWI sequences); CT angiography/
venography or magnetic resonance angiography/venography; digital-
subtraction angiography; ultrasound: transthoracic echocardiography
with bubble contrast and consideration of transesophageal
echocardiography
Other Urine dipstix; ECG Microbiology: Sputum TB culture; Holter ECG
Abbreviations: ADAMT313 5 ADAM metallopeptidase with thrombospondin type 1 motif, 13; CXCL13 5 B lymphocyte chemoattractant chemokine (C-X-
C motif) ligand 13; DWI 5 diffusion-weighted imaging; FBC 5 full blood count; FLAIR 5 fluid-attenuated inversion recovery; GRE 5 gradient recall echo;
Hb SS 5 hemoglobin for sickle cell disease; IgG 5 immunoglobulin G; LDH 5 lactate dehydrogenase; RPR 5 rapid plasma reagin; T1 5 T1-weighted
sequence; T2 5 T2-weighted sequence; TB 5 Mycobacterium tuberculosis; U 1 E 5 urea and electrolyte; VDRL 5 Venereal Disease Research Laboratory;
VZV 5 varicella zoster virus; WCC 5 white cell count.
Table 1 Possible causes of HIV-related ischemic stroke
Ischemic Reported prevalence, %
HIV-associated vasculopathy 20–327,35
Opportunistic infections or neoplasia 13–2832,35,e9
Cardioembolism 5–1532,35,e10
Coagulopathy 19–497,32,35
Adapted from Benjamin et al.4 Lancet Neurology (review).
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Table 3 Diagnostic criteria for the etiology of HIV-related arterial ischemic stroke
Etiology Confirmed Probable Tests
Tuberculosis infection Brain histopathology/CSF evidence of MTB
(AFB, culture, or PCR-positive), plus evidence
of endarteritis obliterans on histology.18
A score$12, based on clinical, CSF, cerebral
brain imaging criteria, or evidence of TB
elsewhere.18
Minimum: TB CSF microscopy, biochemistry,
AFB stain, unenhanced head CT and chest
x-ray. Optimum: CSF/brain histopathology/
sputum TB culture/TB PCR, and head MRI
with contrast.
Cryptococcus Brain histopathology/CSF evidence of
Cryptococcus (positive India ink, culture, or
antigen), plus evidence of endarteritis
obliterans on histology.
Evidence of Cryptococcus in the blood
(culture/antigen) but a negative CSF.
Minimum: Blood culture/CSF India ink stain.
Optimum: CSF culture/antigen detection,
brain histopathology.20
Syphilisa Brain histopathology confirmation of Tp
spirochetes by immunohistochemistry with
associated endarteritis obliterans or active
disease in the blood (positive [Tp EIA 1
TPPA]1 [VDRL or RPR] of more than a 4-fold
change in titer]) and positive CSF VDRL/
RPR.b,24
Active disease in the blood (positive [Tp EIA
1 TPPA] 1 [VDRL or RPR] of more than a 4-
fold change in titer]) and .20 CSF white
cells and negative CSF VDRL/RPR.
Minimum: (Tp EIA 1 TPPA) 1 (VDRL or RPR)
blood tests, CSF microscopy and
biochemistry. Optimum: VDRL/RPR/
chemokine (C-X-C motif) ligand 13.
VZV Brain histopathology evidence of vasculitis
and isolation of VZV (in situ hybridization,
PCR, or antigen/antibody detection using
immunohistochemistry) or positive
monospecific intrathecal VZV-IgG index/CSF
VZV PCR.29,e11
Varicella zoster in a trigeminal or cervical
distribution within 12 wk, before the onset
of stroke, in the absence of histology or
laboratory confirmatione11 and CSF VZV
PCR-negative (or CSF testing not available)
and blood VZV-IgG–positive.29
Minimum: Nil in the presence of a typical
rash, blood VZV-IgG. Optimum: CSF VZV-
IgG index (the index will be determined by
serum/CSF ratio of albumin and VZV-IgG),31
PCR, or brain histopathology examination.
Cardio-
thromboembolism
Presence of high-risk cardio-thromboembolic
lesions as detailed in the TOAST
classification or evidence of infective and
marantic endocarditis.5
Presence of medium-risk cardio-
thromboembolic lesions as detailed in the
TOAST classification.5
Minimum: ECG and transthoracic
echocardiography.Optimum: Holter ECG and
optimal echocardiography (e.g.,
transthoracic with bubble contrast and
consideration of transesophageal
echocardiography).5
Accelerated
atherosclerotic
vasculopathy
Brain histopathology consistent with
atherosclerosis, irrespective of age or
exposure to vascular risk factors or intra/
extracranial carotid stenosis ($50% or
complete occlusion), supplying the affected
ischemic field/a mobile thrombus in the
aortic arch and age .45 y or age #45 y and
exposed to traditional risk factors or
hepatitis C.
Age .45 y or #45 y and exposed to
traditional vascular risk factors or hepatitis
C plus evidence of one of the following: (1)
clinical history suggestive of extra/
intracranial atherosclerosis (i.e., TIA/
ischemic heart disease/peripheral vascular
disease), (2) significant stenosis ($50%) in
an intra/extracranial nonaffected vascular
territory, (3) nonsignificant stenosis ($30
and ,50%) in an intra/extracranial artery.
Minimum: Unenhanced head CT (the ideal
should include magnetic resonance or CT
angiography). Carotid/vertebral duplex (in
the absence of noninvasive angiography).
Transthoracic echocardiograph. Optimum:
Head MRI, CT angiography or magnetic
resonance angiography or digital-subtraction
angiography.5 Optimal echocardiography.
Brain histopathology. Hepatitis C serology.
Nonatherosclerotic
vasculopathy
Brain histopathology demonstrating intimal
hyperplasia and degenerate elastica in the
absence of atherosclerosis and vasculitis,
irrespective of age or exposure to vascular
risk factors or intra/extracranial carotid
stenosis ($50% or complete occlusion),
supplying the affected ischemic field 6
luminal thrombus with or without aneurysmal
dilatation and age #45 y and absence of
traditional risk factors.34,35
Age #45 y and free of exposure to
traditional vascular risk factors and hepatitis
C, plus evidence of one of the following: (1)
significant stenosis ($50%) supplying the
nonaffected ischemic field, (2) nonsignificant
stenosis ($30 and ,50%) in an intra/
extracranial artery.
Minimum: Unenhanced head CT (the ideal
should include magnetic resonance or CT
angiography). Carotid/vertebral duplex (in
the absence of noninvasive angiography).
Transthoracic echocardiograph. Optimum:
Head MRI head with contrast, CT
angiography or magnetic resonance
angiography or digital-subtraction
angiography.5 Hb SS. Optimum:
Echocardiography. Brain histopathology.
HIV-associated
vasculitis
Histopathology or classic angiographic features
of vasculitis within the CNS.43,45,48,e12
CT/MRI confirmation of an acute and/or
chronic ischemic change in more than one
vascular territory, involving any or all of
cortical, subcortical, and deep white matter
distribution.48,e12
Minimum: Unenhanced head CT (the ideal
should include magnetic resonance or CT
angiography). Optimum: Hepatitis B 1 C
serology, CT (with contrast)/MRI (with
contrast) and CT angiography or magnetic
resonance angiography or digital-subtraction
angiography. Histopathology examination.
Small vessel disease Brain histopathology of small vessel disease
demonstrating evidence of hyaline
arteriolosclerosis and lipohyalinosis or at
least one traditional clinical lacunar
syndromesc and CT/MRI lesion with
a diameter of #20 mm.5,51
Presence of one traditional clinical lacunar
stroke syndromec,d and a normal
unenhanced head CT within 24 h of index
stroke.e
Minimum: Unenhanced CT. Optimum: MRI
head and histopathology examination.
Antiphospholipid
syndromef
Presence of anti-b2-glycoprotein 1 antibody
in combination with anticardiolipin antibody
of IgG or IgM or lupus anticoagulant present
in plasma serum, in medium, or high titer (i.e.,
.40 GPL or MPL units, or .99th
percentile)55 and persistence of medium to
high titers of these antibodies for .12 wk.
Presence of anti–b2-glycoprotein 1 antibody
in combination with anticardiolipin antibody
of IgG or IgM or lupus anticoagulant in
plasma or serum, in medium or high titer (i.e.,
.40 GPL or MPL units, or .99th
percentile).55 Present at one time point, or
on 2 occasions separated by ,12 wk.
Minimum: Lupus anticoagulant,
anticardiolipin antibody, and anti–b2-
glycoprotein 1 antibody and unenhanced CT
(the ideal should include a CT, head MRI, and
noninvasive angiography). Optimum:
Histopathology, MRI; CT angiography plus
CT venography or magnetic resonance
angiography plus magnetic resonance
venography.
Continued
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(e.g., those with stroke); this could be useful in rul-
ing out neurosyphilis, especially in asymptomatic
cases but its utility in the context of HIV infection
remains unclear.26 An additional new approach that
has been validated in anHIV population, andmay prove
useful in the future, is CSF CXCL13 (B cell chemo-
attractant; chemokine [C-X-C motif] ligand 13).27
Varicella zoster virus. The diagnosis of VZV vascul-
opathy is currently based on a positive CSF VZV–
immunoglobulin G (IgG) or PCR.28,29 Although
most hospitals rely on CSF VZV PCR, its use is
limited by its lower sensitivity in stroke syn-
dromes.29 HIV infection can impair the blood–brain
barrier; as a result, blood VZV-IgG may leak into
the CSF.30 Therefore, to overcome this limitation,
diagnosis of VZV CNS vasculopathy should ideally
involve calculating the VZV-antibody index.30,31
Furthermore, because other illnesses, including
HIV, can cause a polyspecific intrathecal immune
response, calculating the IgG antibody index for
other viruses (e.g., rubella, measles, or herpes sim-
plex [HSV]) will help to confirm the presence or
absence of a monospecific antibody response to
VZV-IgG.31 In the classic VZV stroke syndrome,
delayed contralateral hemiparesis typically presents
several weeks after acute herpes zoster ophthalmicus
infection.29 We acknowledge that until intrathecal
VZV-antibody testing becomes widely available, the
diagnosis of VZV vasculopathy will largely be based
on CSF PCR and/or the clinical features of stroke
following a history of zoster rash in a corresponding
distribution.29
Other infections. HIV could potentially increase
the rate of other CNS infections, such as HSV-1,
cytomegalovirus, Epstein-Barr virus, toxoplasma,
and fungal infections (e.g., aspergillosis, nocardio-
sis, and histoplasmosis), and these are potentially
associated with stroke. However, there is a limited
description in the literature of stroke directly
related to these infections, suggesting that they
may be less important.7,32
Cardio-thromboembolism. The criteria for cardio-
thromboembolism are based largely on the TOAST
classification.5 We however modified this to also
include marantic (noninflammatory and nonbacterial)
endocarditis in the high-risk group.33
HIV-associated vasculopathy.HIV-associated vasculop-
athy was initially assigned to a pathologic phenotype
with vessel wall abnormality in the absence of athero-
sclerosis or vasculitis.34,35 However, we found that
vasculopathy, defined as intimal hyperplasia more
than expected for age, also encompassed other path-
ologic phenotypes of stroke found in HIV infection,
thus creating confusion in the literature. Examples
included atherosclerosis, HIV-associated vasculitis,
and SVD. In our recent review, we were
deliberately inclusive by defining HIV-associated
Table 3 Continued
Etiology Confirmed Probable Tests
Thrombotic
thrombocytopenic
purpura
ADAMT313 levels ,10% or anti-
ADAMT313 antibody.59,60 Brain
histopathology with platelet thrombi in the
small vessels.58
1 of 2 laboratory criteria: (1)
thrombocytopenia,g (2) microangiopathic
hemolytic anemiah,59 and 2 of 4 clinical or
laboratory criteria: (1) fever, (2) intravascular
thrombi generation, (3) renal dysfunction, (4)
1.5 times elevation of LDH.59
Minimum: FBC and blood film and urine
dipstix assay and unenhanced CT. Optimum:
Imaging to type stroke (venous stroke may
be involved): head MRI and CT angiography
plus CT venography or magnetic resonance
angiography plus magnetic resonance
venography.48 Blood test: clotting profile,
fibrinogen, U 1 E, LDH, ADAMTS13 levels,
and anti-ADAMT313 antibody.60 Brain
histopathology.
Abbreviations: ADAMT313 5 ADAM metallopeptidase with thrombospondin type 1 motif, 13; AFB 5 acid fast bacilli; FBC 5 full blood count; Hb SS 5
hemoglobin for sickle cell disease; IgG5 immunoglobulin G; IgM5 immunoglobulin M; LDH5 lactate dehydrogenase; (M)TB5 (Mycobacterium) tuberculosis;
RPR 5 rapid plasma reagin; TOAST 5 Trial of Org 10172 in Acute Stroke Treatment; Tp EIA 5 treponema enzyme immunoassay; TPPA 5 Treponema
pallidum particle agglutination assay; U 1 E 5 urea and electrolyte; VDRL 5 Venereal Disease Research Laboratory; VZV 5 varicella zoster virus.
Definitions assume the clinical entry criteria of ischemic arterial stroke and HIV infection.
a Intracranial meningovascular complications are more common than extracranial changes.
bRPR is less sensitive than VDRL.
c The following 4 syndromes were recognized: pure motor stroke, pure sensory stroke, sensorimotor stroke, and ataxic hemiparesis (including dysarthria-
clumsy hand syndrome). In the absence of cortical involvement.
dThe presence of a visual field defect, evidence of higher cerebral dysfunction (e.g., dysphasia, visuospatial disturbance, predominantly proprioceptive
sensory loss) on standard clinical testing, or features that clearly localize the lesion in the vertebrobasilar distribution (e.g., gaze palsies or crossed deficits
but not nystagmus or dysarthria) exclude the diagnosis of lacunar syndrome.e13
e There should be careful consideration for a psychogenic cause of symptoms in those with normal unenhanced CT within 24 hours of index stroke.55
fHistopathology confirmation is not essential for a confirmed diagnosis but, if used, thrombosis should be present without significant evidence of
inflammation in the vessel wall.
g Thrombocytopenia 5 platelet count of ,100,000/mm3; microangiopathic hemolytic anemia 5 hemoglobin level of ,12 g/dL for males and 11 g/dL for
females and detection schistocytes (fragmented erythrocytes) on blood film.
h Fever (.37.7°C); presence of thrombi in the circulation 5 elevated D-dimer or fibrinogen ,1.0 g/dL; renal dysfunction 5 anuria, oliguria, hematuria,
proteinuria, or serum creatinine greater than twice the upper limit of normal, or an abnormal result for urine dipstix assay; LDH elevated at 1.5 times the
upper limit of normal (due to systemic tissue ischemia and to a lesser extent hemolysis).
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vasculopathy as an abnormality of the cerebral blood
vessels that results directly or indirectly from HIV
infection but excluding vasculitis due to
opportunistic infections (figure 2).4 Each of the
recognized phenotypes will now be discussed in turn.
Accelerated atherosclerotic vasculopathy.Atherosclerosis
is pathologically defined by plaque formation, con-
sisting of foam cells, a lipid core, and a fibrous
cap.36 It predominately affects large- to medium-
sized vessels, and increases with age and exposure to
traditional and emerging vascular risk factors such
as hypertension, diabetes, smoking, high choles-
terol, and hepatitis C.37,38 Diagnosis is largely based
on radiologic evidence, characterized by significant
(.50%) stenosis of the intra/extracranial artery (or
its main branches) supplying the affected vascular
field.5 Atherosclerosis is accelerated in HIV popu-
lations, occurring up to 2 decades earlier than
expected.39 Chronic inflammation caused by
incomplete suppression of HIV or dyslipidemia
associated with some HIV treatments is believed
to be the underlying mechanism.4
Nonatherosclerotic vasculopathy. Nonatherosclerotic
stroke also affects large- to medium-sized vessels; inti-
mal hyperplasia that can progress to a stenotic or
aneurysmal lesion is characteristic.34,35 Of note, in
this condition, there is no evidence of atherosclerosis
or vasculitis.34,35,40 After repeated damage to the vas-
cular endothelium by HIV and/or its viral particles, it
is conceivable that vessel wall remodeling arises; this
has been described in a recent histopathology study.40
The vasculopathic changes are not dissimilar to ob-
servations seen in sickle cell disease in which repeated
damage also occurs.41 Radiologic diagnosis is usually
relied on but this does not distinguish nonatheroscler-
otic from atherosclerotic vasculopathy. However,
young age of onset and the absence of traditional
vascular risk factors do discriminate.34,35 Clinical
Figure 2 Different pathologic description of vasculopathy associated with HIV infection
(A, B) Atherosclerotic vasculopathy. (C) HIV-associated vasculitis. (D, arteriolosclerosis; E, lipohyalinosis) Small vessel dis-
ease. (F) Nonatherosclerotic vasculopathy. (A–E) From personal archives. (F) Reproduced with permission from the Archives
of Neurology. 2006. 63: 1640–1642. Copyright© 2006 American Medical Association. All rights reserved.34
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conditions associated with atherosclerotic disease
such as previous TIA, ischemic heart disease, or
peripheral vascular disease are seldom reported in this
group. In time, our understanding will expand to
determine whether nonatherosclerotic vasculopathy
is a precursor of atherosclerosis, a spectrum of HIV-
associated vasculitis, or an independent process.
HIV-associated vasculitis. The association of HIV
and cerebral vasculitis has been reported in a few
case series.42–45 It affects vessels of all sizes. Vascu-
litis can either be caused by infection, where direct
invasion of the pathogen leads to proliferation and
inflammation of the vessel wall (as is seen, for
example, in VZV), or by noninfectious immune-
mediated mechanisms (as seen in hepatitis B and
polyarteritis nodosa).46,47 Although a pathogen
may be indirectly involved in the latter, this type
of vasculitis does not have direct vessel wall inva-
sion by the pathogen. Thus far, histopathologic
studies of HIV-associated cerebral vasculitis have
failed to demonstrate HIV in the vessel wall,
suggesting an immune-mediated mechanism.4 A
temporal relationship between starting HIV treat-
ment and the occurrence of a stroke might also
point to an immune reconstitution syndrome,
with HIV infection being an important precipitant
of vasculitis.2
HIV-associated vasculitis is characterized by a sin-
gle organ vasculitis (i.e., limited to the brain).46 Diag-
nosis usually involves identifying clinical and
radiologic features and excluding an alternative cause.
Causes of cerebral vasculitis frequently found in HIV
infection include opportunistic infections (VZV,
syphilis, Cryptococcus, TB) and APS; these have been
discussed elsewhere in the article. Hepatitis B may
coexist with HIV and should also be screened for.
There are rarer causes of vasculitis that are inde-
pendent of HIV infection and only screened for in
the presence of high clinical suspicion; examples
include neoplasia (e.g., lung cancer), infections
(e.g., neuroborreliosis), and inflammatory disorders
(e.g., Behçet disease and sarcoid granulomatosis).48
For the purpose of this consensus report, we do not
recommend that these are screened routinely unless
there is a strong clinical suspicion.
Small vessel disease. As a term, SVD covers many
pathologies; the main causes described are associated
with chronic hypertension, hyaline arteriolosclerosis
and lipohyalinosis, and cerebral amyloid angiop-
athy.49 In HIV infection, autopsy series have demon-
strated several pathologic characteristics consistent
with hyaline arteriolosclerosis and lipohyalinosis.50
Protease-based antiretroviral therapy may also be
implicated in the pathogenesis of SVD.8 The diagno-
sis of HIV-related SVD is largely based on radiology
criteria51; this defines SVD as causing a recent infarct
of less than 20 mm in the appropriate clinical context.
In reality, this may not discriminate medium to small
vessel disease from true SVD.
Coagulopathy. Although some studies have reported
a high prevalence of coagulopathy in HIV-related
ischemic stroke, the causal evidence for arterial-
related coagulopathy, namely, APS and thrombotic
thrombocytopenic purpura (TTP), is limited.4,7,32,35,52,53
Other coagulopathies such as protein C and S deficiency
occur in HIV infection but are associated with venous
and not arterial strokes.
Antiphospholipid syndrome. More than 20% of APS
cases present as a stroke.54 The revised classification
criteria for APS (2006) require both clinical (i.e.,
ischemic stroke) and laboratory criteria for diagnosis
(i.e., a positive anti–b2-glycoprotein I [anti-b2GP1]
or anticardiolipin antibodies [ACL] or lupus antico-
agulant [LA] detected in the blood and persisting for
.12 weeks).55
There is some evidence of the usefulness of these cri-
teria in diagnosing stroke caused by APS. Anti-b2GP1
and LA are strongly associated with stroke.56 However,
the evidence for ACL as a predictor of APS and stroke is
conflicting.56,57 Furthermore, HIV is associated with
ACL and LA but not anti-b2GP1.52 As anti-b2GP1
is specific for stroke in HIV populations, the con-
sensus was to refine the laboratory definition to
include the detection of anti-b2GP1 in combination
with ACL or LA. Because APS is found mostly in
young populations, we have recommended testing
only in those younger than 55 years.54
Thrombotic thrombocytopenic purpura. TTP is a blood
disorder that causes microscopic clots in the small ves-
sels.58 HIV may be a direct precipitant of TTP
through damage of vascular endothelial cells resulting
in dysfunction, localized thrombin generation, and
consumption of ADAMTS13 (a metalloprotease
enzyme that cleaves von Willebrand factor).59 Diag-
nosis of TTP requires 2 major criteria (e.g., throm-
bocytopenia, microangiopathic hemolytic anemia,
and neurologic signs) and at least 2 minor criteria
(fever, renal dysfunction, presence of thrombi in the
circulation, and elevated lactate dehydrogenase).
Deficiency or antibody against ADAMTS13 confirms
the diagnosis of TTP and helps to discriminate
thrombocytopenia, microangiopathic hemolytic ane-
mia occurring independently from TTP.59,60
Although testing for ADAMTS13 is not routine in
clinical laboratories, it is necessary to confirm TTP in
the research setting. In the context of HIV-associated
stroke, this TTP classification was thought to be
appropriate without modification.
Other etiologies. This list of etiologies is not exhaus-
tive; there are other plausible mechanisms in HIV-
related stroke but minimal evidence in the literature
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to support an association (e.g., systemic vasculitides,
extra/intracranial arterial dissection, hyperviscosity
syndrome, and other causes in an aging HIV
population). There are also etiologies described in
young populations that may co-occur in individuals
with HIV infection (e.g., hereditary causes of
stroke and drug-induced vasculopathy). A thorough
clinical history and examination will direct
additional investigations for these rarer causes of
stroke. Future research studies or descriptive
publications should provide as much clinical and
radiologic information as possible to aid our
understanding.
Stroke mimics. Approximately 15% of patients pre-
senting with an acute focal neurologic deficit will have
a stroke mimic, in HIV endemic populations.2 Some
infections that can lead to a stroke can also mimic
stroke. Mimics include toxoplasma infection, pro-
gressive multifocal leukoencephalopathy, viral
encephalitides (e.g., HIV, HSV-1, cytomegalovirus),
fungal infections (e.g., cryptococcoma), lymphoma,
tuberculoma, and HIV-associated tumefactive
demyelination.e1–e3 The selection of appropriate
imaging (ideally a head MRI) is essential for the
exclusion of these stroke mimics.
Biomarkers in cerebrovascular disease. Several promis-
ing candidate biomarkers associated with vascular
disease have been identified (e.g., MCP-1,
sCD14, cerebral vasoreactivity).e4,e5 Although
some biomarkers, such as tumor necrosis factor
receptors 1 and 2, interleukin 6, and highly
sensitive C-reactive protein, are elevated in HIV
infection and predict non-AIDs complications, the
association with vascular disease subtype remains
largely uncertain.e6,e7 Such biomarkers could prove to
be valuable in the future, especially in the context of
HIV-associated vasculopathy.
DISCUSSION In this consensus statement, we have
refined several preexisting case definitions for causes
of stroke in people with HIV and developed new def-
initions for HIV-associated vasculopathy. We also
produced an algorithm to assign a diagnosis when
multiple etiologies arise.
Stroke in low- to middle-income regions is
increasing. In many of these regions, HIV is preva-
lent, and younger populations are more likely to have
infectious causes of stroke. We will only begin to
understand the different mechanisms in HIV-
related stroke if we have robust case definitions and
diagnostic algorithms.
Our vertical algorithm adopts a hierarchical
approach, giving greater weight to those etiologies
that are well established and or for which there
are treatment implications. We also defined
a “resource-sensitive” minimum battery of inves-
tigations to help determine such etiologies. Most
research studies will benefit from this approach.
Validation in prospective cohorts will help to
determine its utility in clinical practice.
Recent work has shown an association between
HIV infection and intracerebral hemorrhage.e8
Future algorithms may need to also incorporate this
pathologic type of stroke.
An important limitation is relying on head CT
alone. The challenge is with classifying subtypes
of HIV-associated vasculopathy when the pathol-
ogy is intracranial and therefore not captured by
duplex carotid Doppler. Although infrequent, it
could lead to cases being misclassified as crypto-
genic stroke. There is also the risk of misclassifying
SVD; this could be minimized by more than one
radiologist reviewing the images and a consensus
determined.
We think our pragmatic approach to classifying
ischemic stroke would allow more refined systematic
investigations of subtype-specific etiologies and
therapies.
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